药捷安康-B(02617)：TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的中国II 期临床试验获批开展

智通财经07-01

智通财经APP讯，药捷安康-B(02617)发布公告，公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤(MCL)的II期临床试验，已于2026年7月1日获国家药品监督管理局(NMPA)批准。本试验为一项评价TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的多中心、开放标签、剂量探索和扩展的II期研究。TT-01488是一款公司自主开发的新型的、非共价的BTK...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2648451055?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-01 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648451055","market":"fut","top_or_hot":-1,"title":"药捷安康-B(02617)：TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的中国II 期临床试验获批开展","media":"智通财经","content":"<div>\n<p>智通财经APP讯，药捷安康-B(02617)发布公告，公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤(MCL)的II期临床试验，已于2026年7月1日获国家药品监督管理局(NMPA)批准。本试验为一项评价TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的多中心、开放标签、剂量探索和扩展的II期研究。TT-01488是一款公司自主开发的新型的、非共价的BTK...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1461946.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药捷安康-B(02617)：TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的中国II 期临床试验获批开展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药捷安康-B(02617)：TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的中国II 期临床试验获批开展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-01 19:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1461946.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，药捷安康-B(02617)发布公告，公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤(MCL)的II期临床试验，已于2026年7月1日获国家药品监督管理局(NMPA)批准。本试验为一项评价TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的多中心、开放标签、剂量探索和扩展的II期研究。TT-01488是一款公司自主开发的新型的、非共价的BTK...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1461946.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2347655156.SGD","symbol_name":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1461946.html","article_id":"2648451055","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648451055","pubTimestamp":1782905809,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，药捷安康-B 发布公告，公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的II期临床试验，已于2026年7月1日获国家药品监督管理局批准。本试验为一项评价TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的多中心、开放标签、剂量探索和扩展的II期研究。多项临床证实BTK抑制剂联合抗CD20单抗可提升套细胞淋巴瘤一线治疗疗效。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","IE00B3CCJ633.GBP":"GUINNESS SUSTAINABLE ENERGY \"C\" (GBP) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","IE00B2PGVK34.USD":"GUINNESS SUSTAINABLE ENERGY \"C\" (USD) ACC","LU0323240290.USD":"HSBC GIF GLOBAL EQUITY CLIMATE CHANGE \"AD\" INC","BK1233":"餐馆","TT":"Trane技术","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0323239441.USD":"HSBC GIF GLOBAL EQUITY CLIMATE CHANGE \"AC\" ACC","IE00BGHQF417.EUR":"GUINNESS SUSTAINABLE ENERGY \"C\" (EUR) ACC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","LU0070217475.USD":"JPM GLOBAL SELECT EQUITY \"A\" ACC","BK1161":"生物科技","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4585":"ETF&股票定投概念","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","LU2211817866.USD":"Allianz Food Security AT Acc USD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2394011477.USD":"JPMORGAN CLIMATE CHANGE SOLUTIONS \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU0210533765.USD":"JPM GLOBAL GROWTH \"A\" (USD) ACC","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","BK4086":"建筑产品","LU0238689110.USD":"贝莱德环球动力股票基金","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4504":"桥水持仓","02617":"药捷安康-B","01488":"百福控股","LU2279689827.SGD":"JPMorgan Investment Funds - Global Income Sustainable A (mth) SGD-H","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","BK4588":"碎股"},"translate_title":"Yaojieankang-B (02617): TT-01488 tablets combined with anti-CD20 monoclonal antibody regimen for the treatment of mantle cell lymphoma in China Phase II clinical trial approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TT":1.5,"02617":1.5,"01488":1.5},"content_text":"智通财经APP讯，药捷安康-B(02617)发布公告，公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤(MCL)的II期临床试验，已于2026年7月1日获国家药品监督管理局(NMPA)批准。本试验为一项评价TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的多中心、开放标签、剂量探索和扩展的II期研究。TT-01488是一款公司自主开发的新型的、非共价的BTK抑制剂。激酶谱筛选显示其靶点活性优异，对EGFR、Tec亲和力低，激酶选择性更优，能减少脱靶抑制，降低房颤、出血等毒副作用，安全性潜力更佳，且在肿瘤淋巴细胞异种移植模型中展现出良好抗肿瘤活性。多项临床证实BTK抑制剂联合抗CD20单抗可提升套细胞淋巴瘤(MCL)一线治疗疗效。TT-01488在已完成的I期临床中，10例疗效可评估的非母细胞型MCL患者中，客观缓解率(ORR)为70%，包括4例完全缓解及3 例部分缓解。其独特作用机制搭配CD20单克隆抗体可协同靶向杀伤与免疫作用，有望构建高效、低毒的“去化疗”一线方案。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648451055","isCrawlerRequest":true}